Dr. David S. Young awarded "Most Innovative" award by the Association of
Chinese Canadian Entrepreneurs
TORONTO, April 7 /PRNewswire-FirstCall/ - ARIUS Research Inc. (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that Dr. David S. Young, President and Chief Executive Officer, received the "Most Innovative" award at the Chinese Canadian Entrepreneur Awards, held on April 5th, 2008 in Toronto, Ontario.
"The FunctionFIRST(TM) antibody discovery platform pioneered by our CEO is the foundation of our company and exemplifies the exceptional innovation that this award honours," said Warren Whitehead, Chief Financial Officer of ARIUS. "As we transition to a clinical company this year, we are proud that ARIUS' mission to generate and develop anti-cancer, antibody drugs has been recognized through this honour."
The Chinese Canadian Entrepreneur Awards, sponsored by the Association of Chinese Canadian Entrepreneurs (ACCE), annually recognizes high achievements by business people and entrepreneurs who have strengthened the competitiveness of Chinese Canadian business community in the global market. The Most Innovative Award is presented to an individual, team of individuals or company who have demonstrated exceptional innovation in their given field and contributed great value to the marketplace.
ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com.
Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at http://www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.
|SOURCE ARIUS Research Inc.|
Copyright©2008 PR Newswire.
All rights reserved